The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
CureVac N.V(NASDAQ:CVAC) 
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy an...
Website: https://www.curevac.com/
Founded: 2000
Full Time Employees: 500
CEO: Franz-Werner Haas
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
CureVac N.V Days Payable Outstanding ttm (DPO)
CureVac N.V Days Receivable Outstanding ttm (DSO)
CureVac N.V Days Inventory Outstanding ttm (DIO)
CureVac N.V Op Cashflow Per Share ttm
CureVac N.V Free Cashflow Per Share ttm
CureVac N.V Cash Per Share ttm
CureVac N.V P/S ratio ttm
CureVac N.V (GAAP) P/E ratio ttm
CureVac N.V P/B ratio ttm
No extra charts and metrics for this ticker.